Larazotide formulations
US12337024B2 · kind B2 · utility
0Cited by
4References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 14, 2020 |
| Grant date | Jun 24, 2025 |
| Priority date | — |
| Expiry date | Dec 25, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides, in part, compositions comprising a peptide that is larazotide or larazotide derivative, or salt thereof, contained within a matrix that provides for controlled release and sustained release formulations. The present invention contemplates that these compositions, formulations and methods can be useful for treating diseases and disorders of the small bowel.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.